Retrospective Cohort Study
Copyright ©The Author(s) 2021.
World J Gastrointest Pathophysiol. May 22, 2021; 12(3): 40-50
Published online May 22, 2021. doi: 10.4291/wjgp.v12.i3.40
Table 1 Baseline demographics

Training (n = 715)
Validation (n = 312)
P value
Age (yr)45.6 (10.7)44.5 (11.1)0.1
Male/female (%)66/3466/341.0
Platelets (× 109/L)186.7 (64.4)190.6 (68.2)0.4
Alanine aminotransferase (IU/L)103.8 (88.1)105.1 (89.1)0.8
Aspartate aminotransferase (IU/L)69.9 (55.0)68.0 (53.3)0.6
Albumin (g/dL)3.9 (0.46)3.9 (0.39)0.2
Alkaline phosphatase (IU/L)82.3 (39.2)79.0 (29.2)0.1
Prothrombin time (s)13.0 (1.3)12.9 (1.1)0.3
Total bilirubin (mg/dL)0.81 (0.48)0.77 (0.45)0.2
Ishak fibrosis2.4 (1.8)2.3 (1.7)0.3
HAI inflammation8.0 (3.0)7.9 (3.1)0.5
HBV/HCV/HDV (%)23/68/823/68/91.0
Table 2 Spearman correlations between Ishak fibrosis and liver tests within training cohort

R
P value
Platelets-0.49< 0.0001
AST0.51< 0.0001
ALT0.37< 0.0001
Alkaline phosphatase0.35< 0.0001
Prothrombin time0.33< 0.0001
Albumin-0.30< 0.0001
Total bilirubin0.18< 0.0001
Table 3 Area under the curve using selected liver tests within the training cohort
PlateletsALTASTAlkaline phosphataseProthrombin time
0.86 (0.82, 0.90)0.65 (0.59, 0.71)0.76 (0.71, 0.81)0.76 (0.71, 0.81)0.77 (0.71, 0.82)
Table 4 Performance of optimal platelet cut-offs in validation cohort

Platelet cut-off (× 109/L)
AUROC
Sensitivity (%)
Specificity (%)
Positive predictive value (%)
Negative predictive value (%)
Entire validation cohort1430.85 (0.76-0.93)79843398
HBV1430.81 (0.53-1.00)83822998
HCV1430.83 (0.72-0.94)75863198
HDV1430.87 (0.74-1.00)1006047100
Table 5 Performance of platelet cut-offs in training cohort
Platelet counts (× 109/L)
Sensitivity (%)
Specificity (%)
Positive predictive value (%)
Negative predictive value (%)
13067915794
14073864895
14374834494
15078783895